Merck KGaA (MKGAF) is identified as a deeply undervalued pharma play with strong fundamentals and resilience to AI disruption, presenting a compelling entry point. Its diversified segments, including life science, healthcare, and electronics, are expected to generate recurring revenue and benefit from both pharmaceutical and AI-driven chip demand. While near-term EPS declines and electronics headwinds are anticipated, stabilization is projected, with long-term EPS growth and valuation recovery expected from 2026. A "BUY" rating is reiterated for MKGAF, with a fair value target of €175/share and a price target of €135/share, citing attractive risk-adjusted upside.
Merck KGaA (MKGAF) is identified as a deeply undervalued pharmaceutical play, exhibiting strong fundamentals and resilience against AI disruption. An analyst has reiterated a "BUY" rating, projecting a fair value target of €175/share and a price target of €135/share, suggesting attractive risk-adjusted upside. The company's diversified business model, spanning life science, healthcare (biologics), and electronics, is expected to generate recurring revenue. This diversification positions MKGAF to capitalize on both pharmaceutical sector growth and increasing demand for AI-driven chip components. While near-term EPS declines and electronics segment headwinds are anticipated, the analysis forecasts stabilization. Long-term EPS growth and valuation recovery are specifically projected to begin from 2026, indicating a strategic long-term investment horizon.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
strongly positive
Sentiment Score
0.80
Ticker Sentiment
